Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates
Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollme
How this was made
The 30-second read
Why it matters
The enrollment completions de‑risk the pipeline and extend the cash runway, likely supporting the stock in the near term.
Market read
First‑report enrollment milestones provide fresh catalyst for KARD, with potential short‑term upside.
What to watch
The large cash burn needed for Phase 3 could pressure liquidity if data disappoints.
Kardigan reports Q3 2026 net loss of $(58,568) thousand, $(0.64) per share, with R&D up to $64,359 thousand; cash of $591,375 thousand after IPO proceeds
The filing reports no revenue. Net loss for the quarter was $(58,568) thousand against $(60,156) thousand in the prior-year quarter, but total operating expenses rose to $64,815 thousand from $59,074 thousand, R&D rose to $64,359 thousand from $49,139 thousand, and G&A rose to $22,245 thousand from $9,935 thousand. Cash increased on IPO proceeds and the company states its cash supports its data readouts through 2027.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026GAAP | $64.36M | – | – |
| General and administrative expenses, Q3 2026GAAP | $22.25M | – | – |
| Change in fair value of contingent milestone liabilities, Q3 2026GAAP | −$21.79M | – | – |
| Total operating expenses, Q3 2026GAAP | $64.81M | – | – |
| Loss from operations, Q3 2026GAAP | −$64.81M | – | – |
| Interest income, Q3 2026GAAP | $6.24M | – | – |
| Change in fair value of preferred stock tranche obligations, Q3 2026GAAP | nil (shown as dash in table) | – | – |
| Warrant issuance expense, Q3 2026GAAP | nil (shown as dash in table) | – | – |
| Other income (expense), net, Q3 2026GAAP | $11K | – | – |
| Loss before income taxes, Q3 2026GAAP | −$58.57M | – | – |
| Income tax benefit, Q3 2026GAAP | nil (shown as dash in table) | – | – |
| Net loss, Q3 2026GAAP | −$58.57M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, Q3 2026GAAP | $(0.64) | – | – |
| Total comprehensive loss, Q3 2026GAAP | −$60.44M | – | – |
| Research and development expenses, nine months 2026GAAP | $165.8M | – | – |
| General and administrative expenses, nine months 2026GAAP | $54.76M | – | – |
| Change in fair value of contingent milestone liabilities, nine months 2026GAAP | $21.74M | – | – |
| Total operating expenses, nine months 2026GAAP | $242.3M | – | – |
| Loss from operations, nine months 2026GAAP | −$242.3M | – | – |
| Interest income, nine months 2026GAAP | $11.79M | – | – |
| Bargain purchase gain, nine months 2026GAAP | nil (shown as dash in table) | – | – |
| Change in fair value of preferred stock tranche obligations, nine months 2026GAAP | nil (shown as dash in table) | – | – |
| Warrant issuance expense, nine months 2026GAAP | nil (shown as dash in table) | – | – |
| Other income (expense), net, nine months 2026GAAP | −$383K | – | – |
| Loss before income taxes, nine months 2026GAAP | −$230.9M | – | – |
| Income tax benefit, nine months 2026GAAP | nil (shown as dash in table) | – | – |
| Net loss, nine months 2026GAAP | −$230.9M | – | – |
| Net loss per share attributable to common stockholders, basic and diluted, nine months 2026GAAP | $(5.22) | – | – |
| Total comprehensive loss, nine months 2026GAAP | −$233.0M | – | – |
Capital returns
- The filing reports no share repurchases and no dividends.
- Net proceeds from the Company's initial public offering in June 2026 are cited as the primary reason cash, cash equivalents and investments increased (company explanation).
What drove it
- Research and development expenses rose to $64,359 thousand in Q3 2026 from $49,139 thousand in Q3 2025, and to $165,791 thousand for nine months 2026 from $103,752 thousand.
- General and administrative expenses rose to $22,245 thousand in Q3 2026 from $9,935 thousand in Q3 2025, and to $54,755 thousand for nine months 2026 from $38,525 thousand.
- A change in fair value of contingent milestone liabilities of $(21,789) thousand is shown in Q3 2026, and $21,740 thousand for nine months 2026. The filing does not explain this line in the text.
- Interest income increased to $6,236 thousand in Q3 2026 from $1,471 thousand, and to $11,794 thousand for nine months 2026 from $3,371 thousand.
- Clinical milestones reported in the period: enrollment completed in Cohort 2 of the Phase 2b portion of KINSHIP-DCM (danicamtiv), enrollment completed in the Phase 2b KATALYST-AV trial (ataciguat, n=156), and enrollment ongoing in KARDINAL-ASH (tonlamarsen).
Concerns
- The filing reports no revenue for the quarter or the nine months, so the net loss is the principal measure of the period.
- Operating expenses increased year over year in both the quarter and the nine months, with R&D and G&A both higher.
- Net loss per share of $(0.64) for Q3 2026 compares with $(4.43) for Q3 2025. The filing shows weighted-average shares of 92,072,013 for Q3 2026 against 13,574,615 for Q3 2025, and does not attribute the change in per-share loss to any single cause.
- The nine-month contingent milestone line is a charge of $21,740 thousand, while the Q3 line is a credit of $(21,789) thousand. The filing gives no explanation of either figure.
- Topline data for all three programs are expected in 2027. The Phase 3 trials are not yet reported as complete, so the cash balance has to fund the programs until those readouts.
What to watch
- Danicamtiv KINSHIP-DCM Phase 2b topline data, expected in the second quarter of 2027, and the possible adjustment of the Phase 3 portion, which the Company says is enrolling across both cohorts.
- Ataciguat Phase 3 registrational trial update, expected in the first half of 2027.
- Ataciguat KATALYST-AV Week 48 topline data for aortic valve calcium, with measures of cardiac structure and function, expected in the second half of 2027.
- Tonlamarsen KARDINAL-ASH topline data, now expected in the second half of 2027.
- Quarterly R&D and G&A trends, and whether the cash balance of $591.4 million is consistent with the Company's stated runway through 2027.
- Operating cash flow and free cash flow for the period, which the filing does not print.
Balance sheet and cash flow
- Cash, cash equivalents and investments: $591.4 million ($591,375 thousand) as of September 30, 2026, compared with $335,485 thousand as of December 31, 2025.
- The Company states the increase primarily reflects net proceeds from its initial public offering in June 2026, primarily offset by cash used in operations (company explanation).
- Total assets: $649,251 thousand as of September 30, 2026, compared with $390,942 thousand as of December 31, 2025.
- Total liabilities: $76,733 thousand as of September 30, 2026, compared with $55,127 thousand as of December 31, 2025.
- Total redeemable convertible preferred stock: nil (shown as dash) as of September 30, 2026, compared with $586,150 thousand as of December 31, 2025.
- Total stockholders' equity: $572,518 thousand as of September 30, 2026, compared with a deficit of $(250,335) thousand as of December 31, 2025.
- The Company states its current cash runway supports advancement of danicamtiv, ataciguat and tonlamarsen through clinical data readouts and the initiation of Phase 3 trials across all three programs.
Analysis
Kardigan's Q3 2026 release covers a clinical-stage company with no reported revenue. The results are a cost and cash picture. Net loss for the quarter was $(58,568) thousand, compared with $(60,156) thousand in Q3 2025, and loss per share was $(0.64) against $(4.43). The filing's weighted-average share count rose from 13,574,615 to 92,072,013, which the filing links to the period's capital events only through the IPO reference in the cash discussion. Total operating expenses were $64,815 thousand against $59,074 thousand, with R&D at $64,359 thousand against $49,139 thousand and G&A at $22,245 thousand against $9,935 thousand. Interest income of $6,236 thousand against $1,471 thousand offset a large part of the operating loss in the quarter.
For the nine months, the operating picture is larger. Total operating expenses were $242,286 thousand against $142,277 thousand, R&D was $165,791 thousand against $103,752 thousand, and G&A was $54,755 thousand against $38,525 thousand. The contingent milestone line shows a $21,740 thousand charge for nine months 2026 and a $(21,789) thousand credit in Q3 2026. The filing does not explain either figure, so the reader should look at the reconciliation in the full 10-Q.
On the balance sheet, cash, cash equivalents and investments rose to $591,375 thousand at September 30, 2026 from $335,485 thousand at December 31, 2025. The Company attributes the increase primarily to net proceeds from its June 2026 IPO, partly offset by operating cash use. Total assets increased to $649,251 thousand from $390,942 thousand, total stockholders' equity moved to $572,518 thousand from a deficit of $(250,335) thousand, and redeemable convertible preferred stock went from $586,150 thousand to nil. The filing does not print operating or free cash flow, so cash burn for the period cannot be read from this release.
Versus the prior period, the company's operating disclosure centres on three programs: danicamtiv (KINSHIP-DCM Phase 2b cohort 2 enrollment complete, topline expected 2Q 2027), ataciguat (KATALYST-AV enrollment complete at n=156, Week 48 topline expected 2H 2027, Phase 3 update expected 1H 2027), and tonlamarsen (KARDINAL-ASH enrolling, topline now expected 2H 2027). The Company gives no numerical financial guidance in this release. Its cash claim, that funds support data readouts through 2027, is the main forward statement and is not accompanied by a runway figure in months or dollars.
The figures that deserve attention are the operating expense growth in both R&D and G&A, the contingent milestone line, the per-share loss and share count change tied to the IPO, and the cash balance relative to the 2027 readout schedule. No capital returns are reported.
Management, verbatim
Completing enrollment in the Phase 2b portion of our Phase 2b/3 adaptive KINSHIP-DCM trial is a significant milestone for danicamtiv and for people with genetic dilated cardiomyopathy.
Tassos Gianakakos, co-founder, chief executive officer and board chair
For all three of our programs, we have the funding to deliver important value-inflecting data in 2027.
Tassos Gianakakos, co-founder, chief executive officer and board chair
Not in the filing
stated, not guessed- Revenue or collaboration income: no revenue line is printed in the filing.
- Operating cash flow and free cash flow for Q3 2026 and nine months 2026.
- Financial guidance: the filing gives no revenue, expense, tax or cash guidance figures.
- Prior-year and prior-quarter percentage changes for any line: no percentage changes are printed in the filing.
- Prior-quarter (Q2 2026) comparatives: the filing presents Q3 2026 against Q3 2025 and nine months against the prior nine months only.
- Cash runway in months or dollars: the filing states the runway only qualitatively.
- Explanation of the change in fair value of contingent milestone liabilities: the filing prints the figures but gives no narrative.
- Quarterly cash used in operations and the net proceeds from the June 2026 IPO in dollars: the filing describes them qualitatively only.
- Consensus estimates and share price reaction: not provided in the documents and not included.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Kardigan, a precision cardiovascular company, filed its quarterly 8‑K reporting financial results and trial updates.
Ticker impact
SEC Form 8‑K discloses completion of enrollment in Phase 2b cohorts for danicamtiv and ataciguat, and outlines topline data timelines through 2027.
potential upward pressure as investors price in reduced trial uncertainty
Trial enrollment completion is a material catalyst for biotech stocks; no negative data released, cash position strong.
Market effects
Strengthens the cardiovascular biotech subsector by showing progress on multiple late‑stage programs.
Positive for US‑listed biotech firms with similar pipelines.
Limited to investors tracking clinical‑stage biotech developments.
Counterpoint
Without actual efficacy data, the enrollment news may be over‑priced; risk of trial failure remains high.
Key entities
- companyKardigan, Inc.
US‑listed biotech (Nasdaq: KARD) developing danicamtiv, ataciguat, and tonlamarsen.
